Compare Amphastar Pharmaceuticals Inc (AMPH) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs FedEx Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while FedEx Corporation trades at $315.74 (market cap $75.09B). The key difference: FedEx Corporation is far larger — about 90.9× Amphastar Pharmaceuticals Inc's market cap, and FedEx Corporation pays a 1.55% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | FDX | |
|---|---|---|
Market Cap | $826.08M | $75.09B |
Sector | Health | Industrials |
52-Week High | $30.81 | $338.75 |
52-Week Low | $16.87 | $174.81 |
Enterprise Value | $1.22B | $104.72B |
Dividend Yield | — | 1.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
FedEx (FDX) trades at $314.69, up 1.24% on the day, with a bearish technical signal from moving averages but oversold RSI levels. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $6.31 exceeding expectations. The company is executing strategic moves, including the sale of its supply chain unit to CMA CGM for $1.4 billion and a $4.15 billion debt tender offer to reduce leverage. Fundamentals show stable revenue near $88 billion and a net income margin of 4.68%, though operating cash flow declined to $7.04 billion in 2025.
The outlook is mixed; analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain amid competitive pressures from Amazon Logistics. Risks include soft shipping demand and ongoing cost-cutting needs. The stock offers value with a P/E of 16.97, but investors should monitor execution of efficiency initiatives and freight segment performance post-spinoff.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
